Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulse Biosciences (PLSE) Total Current Liabilities (2020 - 2025)

Historic Total Current Liabilities for Pulse Biosciences (PLSE) over the last 6 years, with Q3 2025 value amounting to $9.7 million.

  • Pulse Biosciences' Total Current Liabilities rose 4389.56% to $9.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.7 million, marking a year-over-year increase of 4389.56%. This contributed to the annual value of $10.1 million for FY2024, which is 4989.56% up from last year.
  • Latest data reveals that Pulse Biosciences reported Total Current Liabilities of $9.7 million as of Q3 2025, which was up 4389.56% from $9.0 million recorded in Q2 2025.
  • Pulse Biosciences' Total Current Liabilities' 5-year high stood at $10.1 million during Q4 2024, with a 5-year trough of $5.1 million in Q1 2024.
  • Moreover, its 5-year median value for Total Current Liabilities was $7.0 million (2022), whereas its average is $7.5 million.
  • In the last 5 years, Pulse Biosciences' Total Current Liabilities surged by 15208.39% in 2021 and then tumbled by 2732.08% in 2024.
  • Over the past 5 years, Pulse Biosciences' Total Current Liabilities (Quarter) stood at $6.7 million in 2021, then dropped by 10.84% to $6.0 million in 2022, then grew by 12.16% to $6.7 million in 2023, then soared by 49.9% to $10.1 million in 2024, then dropped by 3.53% to $9.7 million in 2025.
  • Its Total Current Liabilities was $9.7 million in Q3 2025, compared to $9.0 million in Q2 2025 and $7.8 million in Q1 2025.